Integrins are promising targets in the treatment of conditions that range from cancer to acute coronary syndromes. However, the partial agonism exhibited by RGD ligand–based drugs can result in life-threatening complications. A new study provides the structural basis for pure antagonism by a high-affinity integrin ligand and suggests a path to the design of safer integrin inhibitors.
- Johannes F Van Agthoven
- Jian-Ping Xiong
- M Amin Arnaout
